Table 3.
Multivariable Cox regression analysis relating biomarkers to risk of first cardiovascular event - VIDA.
| hs-cTnI (pg/ml) | HRa (95% CI), p | hs-cTnT (pg/ml) | HRa (95% CI), p | NT-proBNP (pg/ml) | HRa (95% CI), p |
|---|---|---|---|---|---|
| Quintile of cardiac biomarkers | |||||
| <2.2 | 1.00 | <3.60 | 1.00 | <28.83 | 1.00 |
| 2.2-<2.9 | 1.26 (0.69, 2.29), 0.46 | 3.60-<5.32 | 1.41 (0.76, 2.60), 0.28 | 28.83-<53.96 | 1.72 (1.03, 2.85), 0.04 |
| 2.9-<3.7 | 1.63 (0.91, 2.92), 0.10 | 5.32-<7.30 | 1.11 (0.59, 2.10), 0.75 | 53.96-<87.98 | 1.53 (0.91, 2.58), 0.11 |
| 3.7-<5.4 | 2.15 (1.23, 3.75), 0.01 | 7.30-<10.41 | 2.16 (1.20, 3.88), 0.01 | 87.98-<156.00 | 1.41 (0.82, 2.43), 0.21 |
| ≥5.4 | 2.57 (1.47, 4.49), <0.001 | ≥10.41 | 3.01 (1.66, 5.48), <0.001 | ≥156.00 | 3.38 (2.04, 5.60), <0.001 |
| Type 3 Test | p<0.001 | p<0.001 | p<0.001 | ||
| Natural logarithm of cardiac biomarkers | |||||
| ln (hs-cTnI) | 1.42 (1.24, 1.62), <0.001 | ln (hs-cTnT) | 2.03 (1.60, 2.59), <0.001 | ln (NT-proBNP) | 1.54 (1.34, 1.76), <0.001 |
| Clinical meaningful cut-off point of cardiac biomarkers | |||||
| Women <16 or men <34 | 1.00 | <14 | 1.00 | <125 | 1.00 |
| Women ≥16 or men ≥34 | 2.29 (1.33, 3.95), 0.003 | ≥14 | 1.89 (1.37, 2.61), <0.001 | 125-299 | 1.52 (1.10, 2.11), 0.01 |
| 300-1000 | 2.92 (1.96, 4.35), <0.001 | ||||
| ≥1000 | 5.81 (3.01, 11.23), <0.001 | ||||
| Type 3 test | p=0.003 | p<0.001 | p<0.001 | ||
a
Adjusted for risk factors in PREDICT CVD v.2019; hs-cTnI, high sensitivity cardiac troponin I; hs-cTnT, high sensitivity cardiac troponin T; NT-proBNP, N-terminal pro b-type natriuretic peptide; the multivariable Cox regression model included the PREDICT CVD v.2019 risk factors and one cardiac biomarker (hs-cTnI or hs-cTnT or NT-proBNP).